ImmunoCellular Therapeutics Ltd. (IMUC.OB) Granted Monoclonal Antibody Technology Patent
ImmunoCellular Therapeutics, Ltd. announced this morning that it has been granted a U.S. patent relating to its monoclonal antibody therapeutics. Patent No. 7,498,129 entitled “Myeloma Cell and Ovarian Cancer Cell Surface Glycoproteins, Antibodies Thereto, and Uses Thereof,” covers the use of IMUC’s antibodies to measure the effectiveness of the company’s proposed treatment of multiple myeloma and ovarian cancer using the company’s proprietary molecular antibodies. “This patent provides additional strength to the growing intellectual property position that we are building around our antibody technologies for the detection and the treatment of cancer,” stated Manish Singh, Ph.D., president and chief executive officer…